AbstractIntroduction
The 'molecular switch' that determines the lipo-and myofibroblast phenotypes is 115 peroxisome proliferator-activated receptor gamma (PPARγ), a member of the retinoid X-116 receptor heterodimer family of the retinoid/steroid/thyroid hormone superfamily of ligand-117 activated nuclear receptors (7). We have previously shown that maintaining a lipofibroblast 118 phenotype prevents hyperoxia-and inflammation-induced neonatal lung injury (5; 18; 28) . 119 Given curcumin's potent antioxidant, anti-inflammatory, and PPARγ-stimulatory properties, 120 in a previous study, we had shown that curcumin treatment could prevent the pathologic 121 effects of hyperoxic exposure on lung development in newborn rats up to 7 days of life (22) . 122
In the current study, we have extended these observations by showing the longer-term 123 preventive effects of the 5 day regimen of newborn hyperoxia with or without curcumin 124 treatment at 21 days of life, consistent with its potential for the treatment and prevention of 125 BPD. We hypothesize that curcumin, by upregulating homeostatic AIF PPARγ signaling, 126 enhances neonatal lung maturation and prevents hyperoxia-induced neonatal lung injury, and 127 that this protective effect is mediated by blocking hyperoxia-induced activation of TGF-β 128 signaling. 129 130 131
Methods and Materials 132 133
In vivo hyperoxia exposure system and animal protocol. First-time pregnant Dawley rat dams were housed in humidity-and temperature-controlled rooms on a 12:12-h 135 light-dark cycle, and allowed food and water ad libitum. On day 22 of pregnancy, the dams 136 delivered naturally. The pups were pooled, randomized, and returned to the nursing dams.
One set of pups was maintained in 95% O 2 , while the other set was maintained in room air 138 (21% O 2 ). Nursing dams were rotated between hyperoxia-and room air-exposed litters every 139 24 h to prevent O 2 toxicity in the nursing dams. Continuous 95% O 2 exposure was achieved 140 in a Plexiglas chamber (77 x 64 x 37 cm) flow-through system. The O 2 level inside the 141
Plexiglas chamber was monitored continuously with an O 2 analyzer (MAXO2, Ceramatec, 142
Maxtec Inc., Salt Lake City, Utah). Experimentally, pups were grouped as controls (21% O 2 143 of newborn rats or 5 days + placebo intraperitoneal saline administration), 21% O 2 + 144 curcumin, hyperoxia only (95% O 2 of newborn rats for 5 days + placebo), or hyperoxia with 145 curcumin (95% O 2 for 5 days + curcumin). Curcumin (Sigma-Aldrich, St. Louis, MO) was 146 first dissolved in dimethylsulfoxide (16 μg/μl), and administered based on the body weight of 147 each animal (5 mg/kg), further diluted with sterile saline to a 50 μl volume, and administered 148 intraperitoneally with a microsyringe once a day. After the 5-day experimental period, both 149 hyperoxia and normoxia-exposed animals were maintained in 21% O 2 until day 21 of life, 150 when the pups were killed using 0.1 ml of Euthasol (390 mg/ml pentobarbital sodium + 50 151 mg/ml phenytoin; Virbac Animal Health, Inc., Fort Worth, Texas) per pup. At sacrifice, the 152 lungs were collected and processed for Western analysis, immunofluorescence staining, 153 triglyceride uptake, or fibroblast isolation (see below TGCTGATTTAAACACTCAAAATCCA-3′ (83 bp). The normalization control was 18S 249 ribosomal RNA. Data were analyzed using a threshold level of fluorescence that was in the 250 linear range of the PCR reaction. The CT value for 18S ribosomal RNA was subtracted from 251 the CT value of the gene to obtain a delta CT (∆CT) value. The relative fold-change for eachgene was calculated using the ∆∆CT method. Results were expressed as the mean ± SE, and 253 considered statistically significant at P < 0.05. 254
255
Statistical analysis-Experiments were reproduced at least three times. Statistical differences 256 between the groups were evaluated by one-way ANOVA followed by Newman-Keuls post 257 hoc test and unpaired Student's t-test as appropriate. P<0.05 was considered to be 258 statistically significant. Values are means ± SE. 259
260

Results
261
Effect of Curcumin on Hyperoxia-Induced Gross Structural Changes 262
21 day old rat lungs exposed to 95% O 2 for the first 5 days of life resulted in a significant 263 decrease in alveolar count (Fig. 1A) , an effect that was blocked by concomitant treatment 264 with curcumin (5 mg/kg, administered intraperitoneally once daily). Curcumin treatment also 265 blocked the decrease in lung alveolar septal thickness (Fig. 1B) caused by the 5 day exposure 266 to 95% O 2. 267 268
Effect of Curcumin on Alterations in Apoptotic and Mesenchymal Markers of Airway 269
Reactivity 270 As for the hyperoxic effect on apoptosis, Western blot analysis of the whole lung lysates 271 showed a decreased Bcl-2/Bax ratio ( Fig. 2A) , confirmed by immunofluoresence staining as 272 a decrease in Bcl-2 and increase in Bax (Fig. 2B, C) protein levels, which was blocked by 273 curcumin treatment. Mesenchymal markers of airway reactivity-fibronectin, vimentin, and 274 calponin (Fig 3A, B , C)-remained increased even at PND21 after 5 days exposure tohyperoxia from PND 1 to 5, an effect that was also confirmed by immunofluoresence 276 staining ( Fig 3D, E) ; this was also blocked by curcumin treatment. As for the effect of 277 hyperoxia on interstitial connective tissue, there was a significant increase in staining for 278 collagen III (Fig. 3F) , which was also blocked by curcumin treatment. To confirm the cell-279 specificity of hyperoxia-induced mesenchymal changes and how curcumin modulates these 280 changes, we next performed double staining for a fibroblast marker, α-smooth muscle actin 281 (α-SMA), and an alveolar type II cell marker, p180 lamellar body protein. As is clear from 282 Fig. 3G , the hyperoxia exposed group showed increased α-SMA staining, restricted 283 specifically to the mesenchymal compartment as evidenced by the lack of co-staining with 284 p180, and this increase was blocked in the curcumin treated group. Turning to the expression 285 of genes relevant to the matrix, we observed significant up-regulation of elastin, tropoelastin, 286
FGFr4, FGFr3, Fibrillin5, Fibrillin2 and Lox (Fig. 4A) by RT-PCR; these effects were 287 blocked by curcumin treatment, with the exception of FGFr4 and r3. The hyperoxia-induced 288 upregulation of elastin and its blockade by curcumin were also confirmed by 289 immunofluorescence (Fig. 4B) . 290 291
Effect of Curcumin on Hyperoxia-Induced Alterations in Triglyceride Uptake ex vivo 292
Sustained deleterious effects of hyperoxia were reflected by a significant decrease in the rate 293 of triolein uptake, a marker for alveolar interstitial fibroblast function, by cultured lung 294 explants of PND21 lungs, an effect reversed by curcumin treatment (Fig. 5) . 295 296
Effect of Curcumin on Hyperoxia-Induced Alterations in Alveolar Fibroblast 297
Proliferation and Apoptosis in vitro 298
Cell proliferation, as determined by the thymidine incorporation assay, was significantly 299 decreased by 95% O 2 exposure of the cultured e19 fibroblasts for 24h (Fig. 6A) , an effect 300 that was reversed in a dose-dependent manner by the curcumin treatment. Consistent with the 301 effects of hyperoxia on apoptosis, treatment of e19 lung fibroblasts with 95% O 2 in culture 302 resulted in an increase in cleaved caspase 3, an effect that was significantly reduced by the 303 curcumin treatment (Fig. 6B) . This effect was also confirmed by immunostaining; following 304 6h synchronization in 0.1% fetal bovine serum (FBS), cultured e19 fibroblasts were exposed 305 to 95% O 2 for 16h, resulting in an increase in staining for cleaved-caspase-3 (Fig 6C) , an 306 effect that was blocked by 1h pre-treatment with curcumin. 307 308
Effect of Curcumin on Hyperoxia-Induced Activation of MAP Kinase Signaling 309
To probe the mechanism of curcumin action, we focused on MAP Kinases, using cultured 310 lung fibroblasts to discern which of the various MAP Kinases were affected by curcumin. 311
Following a 6h synchronization in 0.1% FBS, e19 fibroblasts were exposed to 95% O 2 for 10 312 min, which resulted in significant increases in Erk1/2 activation, expressed as the ratio of 313 phosphorylated/total Erk1/2 protein levels; curcumin pretreatment blocked Erk activation 314 (Fig. 7A) . In accord with these observed effects of curcumin on MAP Kinase signaling, 315 under the same experimental conditions there was an increase in nuclear staining for Erk 1/2, 316 which was blocked by curcumin (Fig. 7D) . Conversely, although hyperoxia increased the 317 amount of phospho-JNK protein, expressed as a ratio to total-JNK, the effect was not 318 affected by curcumin (Fig. 7B) ; likewise, p38, expressed as a ratio to total p38, was 319 unaffected by hyperoxia (Fig. 7C) , indicating the specificity of curcumin's effect on MAP 320
Kinase activation. E19 fibroblasts, pretreated with either UO126, a specific inhibitor ofErK1/2, or curcumin (5μM) were exposed to 95% O 2 for 10 min. Both UO126 and curcumin 322 blocked Erk1/2 activation (Fig. 8A) . 24h exposure of E19 fibroblasts to 95% O 2 with or 323 without UO126 or curcumin blocked the hyperoxia-induced increases in fibronectin, and the 324 increased Bax and decreased Bcl-2 proteins (Fig. 8B) . 325 326
Effect of Curcumin on Hyperoxia-Induced Activation of TGF-β Signaling 327
Previously, we have shown that exposure to hyperoxia activates TGF-β signaling in the 328 neonatal lung, an effect blocked by curcumin (5). It is interesting to note the spontaneous 329 resolution of increased p-Smad3 and Smad 7 proteins at PND21 following the initial 5 day 330 exposure to hyperoxia (Fig. 9A and 9B) . However, Alk-5 (a TGF-β receptor) protein was 331 still significantly increased at PND21 in the hyperoxia exposure group, with at least partial 332 attenuation in the curcumin-treated group (Fig. 9C) . Of note, Smad-7, an inhibitor of TGF-β 333 activation, was markedly increased, even at PND21, in the hyperoxia-exposed, curcumin-334 treated group (Fig. 9B) . Immunostaining for Alk-5 (Fig. 9D ) and Smad 7 (Fig. 9E) Curcumin was previously found to stimulate the key genes necessary for lipofibroblast 357 differentiation, which protects the lung against oxidant injury (22). Furthermore, oxidant 358 injury, which downregulates these genes, was inhibited by curcumin treatment both in vitro 359 and in vivo, thereby preserving the molecular and structural integrity of the alveoli. At the 360 cell-molecular level, curcumin sustained the lipofibroblast phenotype, maintaining its ability 361 to take up triolein, which is cytoprotective against oxidant injury (29), and provides substrate 362 for surfactant phospholipid synthesis by the neighboring alveolar type II cell (27) . 363
Mechanistically, it inhibited oxidative stress and hyperoxic activation of TGF-β signaling, 364 which is thought to be an important causal pathway in the pathogenesis of BPD (1; 5) 365
Curcumin, an active ingredient of the Indian spice turmeric, is known to have potent 367 antioxidant, anti-inflammatory, and antimicrobial properties, making it an interesting dietary 368 therapy for BPD (6). The dose of curcumin used by us was based on its optimal anti-TGF-β 369 effects at 5 mg/kg body weight in our previous experiments (22). This dose is markedly 370 lower than those used in adults by others, either by the oral or parenteral route (6; 10; 12; 25). 371
Our previous investigation into the mechanism of curcumin's cytoprotective effect on 372 neonatal lung injury suggested blockade of hyperoxia-induced TGF-β activation, which 373 modulates fibroblast differentiation via both canonical (Smad) and non-canonical (MAPK) 374 pathways (13; 23; 33; 35). In line with previous observations in a variety of models, we now 375 for the first time document blockade of hyperoxia-induced activation of TGF-β and its down-376 stream non-canonical mediator Erk1/2 by curcumin (4; 23; 26). Since curcumin seems to 377 block both the canonical and non-canonical TGF-β activations, it likely explains the near-378 complete abrogation of hyperoxia-induced neonatal lung injury in our model. Furthermore, 379 extension of the protective effect of curcumin against hyperoxia-induced neonatal lung injury 380 up to PND21 in this current study indicates long-term efficacy of curcumin for the treatment 381 and prevention of BPD. We have examined the effects of curcumin at multiple structural and 382 functional levels, in combination with cellular and molecular perturbations. Using this 383 hierarchical approach, we have found that curcumin acts comprehensively to prevent the 384 deleterious effects of hyperoxic lung injury. Similarly, curcumin has been shown to inhibit 385 bleomycin-induced pulmonary fibrosis by modulating TGF-β signaling (25). Curcumin has 386 also been shown to counteract TGF-β-mediated downregulation of PPARγ in hepatic stellate 387 cells, which are the liver homolog of AIFs (34). However, our study is the first to show thatparenterally-administered curcumin prevents hyperoxia-induced neonatal lung injury long-389 term, suggesting its potential usefulness in preventing BPD. Curcumin provides in vivo protection against hyperoxia-induced damage. 21 day old rat 552 pups exposed to 95% O 2 for the first 5 postnatal days, and then followed subsequently in 553 room air demonstrated a significant decrease in alveolar count (Fig 1A) and significantly 554 increased septal thickness (Fig 1B) , both of which were blocked by concurrent treatment 555 with curcumin (5 mg/kg, administered intraperitoneally once daily). Values are means ± SE; 556 n = 9 animals; n = 20 sections. 557
558
Fig 2 559
Curcumin provides in vivo protection against hyperoxia-induced lung cell apoptosis. In 560 vivo exposure to 95% O 2 for 5 days resulted in a decreased Bcl-2/Bax ratio (Fig 2A) , an 561 effect that was blocked by curcumin treatment (5 mg/kg, administered intraperitoneally once 562 daily) commencing at birth. Values are means ± SE; n = 3. This observation was 563 corroborated by immunofluorescence staining of Bcl-2 (Fig 2B) and Bax (Fig 2C) . 564
565
Fig 3 566
Protective effects of curcumin against hyperoxia-induced increase in markers of 567 pulmonary damage. In vivo exposure to 95% O 2 for 5 days resulted in significant increases 568 in Fibronectin (Fig. 3A) , Vimentin (Fig. 3B) , and Calponin (Fig. 3C) protein levels, which 569 were all blocked by once-daily curcumin treatment (5 mg/kg, administered intraperitoneally 570 once daily). Values are means ± SE; n = 3. Immunofluorescence staining ofParaformaldehyde-fixed, paraffin-embedded PND21 lung sections for Vimentin (Fig. 3D) , 572 Calponin (Fig. 3E) , and collagen III (Fig. 3F ) corroborated these data. Double staining of 573 PND21 lung tissue for the mesenchymal compartment marker, α-smooth muscle actin (α-574 SMA), and epithelial alveolar type II cell marker, lamellar body (Fig. 3G) , showed increased 575 α-SMA staining (arrow pointing to green stain), restricted specifically to the mesenchymal 576 compartment [lack of any evidence of co-staining with p180(arrowhead pointing to red 577 stain)]. 578 579
Fig 4 580
Effect of curcumin on hyperoxia-induced alterations in elastin-related genes. In vivo 581 exposure to 95% O 2 for 5 days resulted in significant increases in elastin, tropoelastin, 582
FGFr4, FGFr3, fibrillin5, fibrillin2 and lox (Fig. 4A) , all of which were blocked by 583 concomitant curcumin treatment (5 mg/kg, administered intraperitoneally once daily) (Real 584 Time PCR data are shown). Values are means ± SE; n = 3. The upregulation of elastin by 585 hyperoxia, and its blockade by curcumin treatment were confirmed by immunofluorescence 586 (Fig. 4B) . 587 588
Fig 5 589
Hyperoxia-induced decrease in triolein uptake, a functional marker for lipofibroblasts, 590 is blocked by curcumin administration. Hyperoxia exposure of PND21 lung explants 591 significantly decreased triolein uptake, an effect that was blocked by curcumin administration 592 (5 mg/kg, administered intraperitoneally once daily). Values are means ± SE; n = 6. 593
Fig 6 595
Curcumin inhibits hyperoxia-induced decrease in cell proliferation and apoptosis in 596 embryonic day 19 (e19) fetal rat lung lipofibroblasts (LIF). 24h hyperoxia-induced 597 decrease in thymidine uptake was significantly blocked by concomitant treatment with 598 curcumin (Fig. 6A) ; n = 6. E19 LIF exposure to 95% O 2 resulted in an increase in cleaved 599 caspase 3, and was also significantly blocked by pre-treatment with curcumin (5 µM); n = 3 600 (Fig. 6B) . Curcumin also inhibited the increase in immunofluoresence staining for cleaved-601 caspase-3 (Fig. 6C) . Values are means ± SE. 602
603
Fig 7 604
Curcumin inhibits hyperoxia-induced p44/p42 activation. Following a 6h 605 synchronization, e19 LIFs were exposed to 95% O 2 for 10 min, resulting in a significant 606 increase in both phospho-p44 and phospho-p42, which were both blocked by 1h pretreatment 607 with curcumin (Fig. 7A) . Similar data were found by immunofluoresence staining (Fig. 7D) . 608
In contrast, hyperoxia-induced activation of SAPK/JNK was not blocked by curcumin pre-609 treatment (Fig. 7B) ; hyperoxia did not induce activation of p-38 MAP Kinase (Fig. 7C) . 610
611
Fig 8 612
Effect of curcumin on hyperoxia-induced activation of MAP kinase (Erk1/2) signaling 613 pathway, and the hyperoxia-induced increase in fibronectin and apoptosis. E19 LIFs 614 were exposed to 95% O 2 for 10 min, resulting in significant increases in both phospho-p44 615 and phospho-p42. 1h pretreatment with UO126 (Erk1/2 inhibitor) or curcumin completely 616 blocked hyperoxia-induced phosphorylation of Erk1/2. (Fig. 8A) . E19 LIF exposure to 95%O 2 for 24h significantly increased fibronectin (Fig. 8B) , and significantly decreased the BCL-618 2/Bax ratio (Fig. 8C) . 1h pretreatment with UO126 or curcumin partially blocked this effect. 619 620 621 622
Fig 9 623
Curcumin protects against hyperoxia-induced activation of the TGF-β pathway. 624
Western blot analysis shows spontaneous resolution of increased p-Smad3 and Smad 7 625 proteins at PND21 following the initial 5 day exposure to hyperoxia ( Fig. 9A and 9B) . 626
However, Alk-5 (a TGF-β receptor) protein was still significantly increased at PND21 in the 627 hyperoxia exposure group, with at least partial attenuation in the curcumin-treated group 628 (Fig. 9C) . Smad-7 was markedly increased, even at PND21, in the hyperoxia-exposed, 629 curcumin treated group (Fig. 9B) . Immunostaining for Alk-5 (Fig. 9D ) and Smad 7 (Fig. 9E) 
